171 related articles for article (PubMed ID: 28427187)
1. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
3. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
[TBL] [Abstract][Full Text] [Related]
4. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
5. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
6. BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation.
Zhu D; Osuka S; Zhang Z; Reichert ZR; Yang L; Kanemura Y; Jiang Y; You S; Zhang H; Devi NS; Bhattacharya D; Takano S; Gillespie GY; Macdonald T; Tan C; Nishikawa R; Nelson WG; Olson JJ; Van Meir EG
Cancer Cell; 2018 Jun; 33(6):1004-1016.e5. PubMed ID: 29894688
[TBL] [Abstract][Full Text] [Related]
7. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
[TBL] [Abstract][Full Text] [Related]
9. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
10. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
[TBL] [Abstract][Full Text] [Related]
13. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
15. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
16. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
17. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
Eslin D; Lee C; Sankpal UT; Maliakal P; Sutphin RM; Abraham L; Basha R
Tumour Biol; 2013 Oct; 34(5):2781-9. PubMed ID: 23686785
[TBL] [Abstract][Full Text] [Related]
19. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
[TBL] [Abstract][Full Text] [Related]
20. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
